4552 — JCR Pharmaceuticals Co Share Price
0.000.00%
Last trade - 00:00- ¥59bn
- ¥76bn
- ¥43bn
- 34
- 37
- 17
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.46 | ||
| PEG Ratio (f) | 0.82 | ||
| EPS Growth (f) | 17.83% | ||
| Dividend Yield (f) | 4.35% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | 1.16 | ||
| Price to Free Cashflow | 133.39 | ||
| Price to Sales | 1.64 | ||
| EV to EBITDA | 23.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.34% | ||
| Return on Equity | -0.42% | ||
| Operating Margin | -0.65% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 24,781 | 30,085 | 51,082 | 34,343 | 42,871 | 39,547 | 40,005 | 13.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -32.63 | +162.16 | +126.7 | -75.36 | +44.78 | -26.83 | +17.83 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment segment engages in the purchase and sale of the medical and research equipment.
Directors
- Shin Ashida CHM (77)
- Toru Ashida SMD (52)
- Mathias Schmidt MDR (53)
- Hiroyuki Sonoda MDR (43)
- Yutaka Honda EXO
- Junichi Ando EXO
- Takayo Egawa EXO
- Kazunori Tanizawa EXO
- Yoshio Hiyama OTH (61)
- Yuko Hayashi IND (56)
- Toshihiro Ishikiriyama IND (68)
- Takashi Suetsuna IND (72)
- Toshihide Yoda IND (58)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 13th, 1975
- Public Since
- March 16th, 1995
- No. of Shareholders
- 20,465
- No. of Employees
- 934
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 121,824,806
- Address
- 3-19, Kasuga-cho, ASHIYA-SHI, 659-0021
- Web
- https://www.jcrpharm.co.jp/
- Phone
- +81 797328591
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 4552
Similar to 4552
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the JCR Pharmaceuticals Co share price?
As of Today at 21:26 UTC, shares in JCR Pharmaceuticals Co are trading at ¥473. This share price information is delayed by 15 minutes.
How has the JCR Pharmaceuticals Co share price performed this year?
Shares in JCR Pharmaceuticals Co last closed at ¥473 and the price had moved by -40.35% over the past 365 days. In terms of relative price strength the JCR Pharmaceuticals Co share price has underperformed the Nikkei 225 Index by -37.14% over the past year.
What are the analyst and broker recommendations for JCR Pharmaceuticals Co?
The overall consensus recommendation for JCR Pharmaceuticals Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the JCR Pharmaceuticals Co dividend yield?
The JCR Pharmaceuticals Co dividend yield is 4.23% based on the trailing twelve month period.
Does JCR Pharmaceuticals Co pay a dividend?
Last year, JCR Pharmaceuticals Co paid a total dividend of ¥20, and it currently has a trailing dividend yield of 4.23%.Looking ahead, the next dividend pay date is 2025-06-01.
When does JCR Pharmaceuticals Co next pay dividends?
We do not have data on when JCR Pharmaceuticals Co is to next pay dividends. The historic dividend yield on JCR Pharmaceuticals Co shares is currently 4.23%.
How do I buy JCR Pharmaceuticals Co shares?
To buy shares in JCR Pharmaceuticals Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of JCR Pharmaceuticals Co?
As of the previous close price of ¥473, shares in JCR Pharmaceuticals Co had a market capitalisation of ¥59bn.
Where are JCR Pharmaceuticals Co shares listed?
Here are the trading details for JCR Pharmaceuticals Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4552
What kind of share is JCR Pharmaceuticals Co?
Based on an overall assessment of its quality, value and momentum JCR Pharmaceuticals Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a JCR Pharmaceuticals Co share price forecast for 2025?
The analyst consensus target price for shares in JCR Pharmaceuticals Co is ¥641. That is 35.51% above the last closing price of ¥473.
Analysts covering JCR Pharmaceuticals Co currently have a consensus Earnings Per Share (EPS) forecast of ¥32 for the next financial year.
Find out moreWhat is the trend in the JCR Pharmaceuticals Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like JCR Pharmaceuticals Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -21.08%.
As of the last closing price of ¥473, shares in JCR Pharmaceuticals Co were trading -20.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the JCR Pharmaceuticals Co PE Ratio?
The JCR Pharmaceuticals Co PE ratio based on its reported earnings over the past 12 months is 12.46. The shares last closed at ¥473.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of JCR Pharmaceuticals Co?
JCR Pharmaceuticals Co's management team is headed by:
- Shin Ashida - CHM
- Toru Ashida - SMD
- Mathias Schmidt - MDR
- Hiroyuki Sonoda - MDR
- Yutaka Honda - EXO
- Junichi Ando - EXO
- Takayo Egawa - EXO
- Kazunori Tanizawa - EXO
- Yoshio Hiyama - OTH
- Yuko Hayashi - IND
- Toshihiro Ishikiriyama - IND
- Takashi Suetsuna - IND
- Toshihide Yoda - IND